Biorestorative Therapies, Inc. insider trading

Every open-market purchase and sale by Biorestorative Therapies, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

No open-market insider trades reported in the last five years.

Does following Biorestorative Therapies, Inc.’s insiders pay?

From October 16, 2012 to April 10, 2024, 10 insiders reported 40 open-market purchases and 2 sales not made under a pre-set plan in Biorestorative Therapies, Inc.

Biorestorative Therapies, Inc.: each insider's record
Insider	Role	Purchases	12 months after their purchases	Beat the S&P 500	Sales	12 months after their sales	Latest report
Broadrick Dale	10% owner	20	—	—	0	—	February 12, 2024
Silva Francisco	VP of Research and Development	6	—	—	1	—	April 10, 2024
Alstodt Lance	President, CEO, COB	3	—	—	0	—	July 25, 2023
Catell Robert B	Director	3	—	—	0	—	May 10, 2018
Desmarais John M	Director	2	—	—	0	—	September 28, 2016
Ryan Charles S.	Director	2	—	—	0	—	December 17, 2015
Tonna Paul Jude	Director	2	—	—	0	—	August 29, 2019
Clyde Mandy D.	VP of Operations	0	—	—	1	—	October 16, 2012
Kristal Robert Eugene	Chief Financial Officer	1	—	—	0	—	April 11, 2022
Swiader Joseph B	Director	1	—	—	0	—	July 2, 2014

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

← Back to Biorestorative Therapies, Inc. · Funds · Politicians